Drugs News and Research

RSS

Genetic variants may help explain who loses more weight and who gets side effects on GLP-1 drugs

A large 23andMe-based GWAS found that common variants in GLP1R and GIPR help explain why some people lose more weight or experience more nausea and vomiting on GLP-1 drugs. The findings suggest genetics may eventually help predict who responds best to semaglutide or tirzepatide and who is more likely to develop side effects.

9 Apr 2026

Targeted diet helps reprogram aggressive neuroblastoma in mice

Researchers highlighted how an arginine- and proline-restricted diet combined with eflornithine reprogrammed MYCN-driven neuroblastoma in mice, pushing tumor cells out of the cell cycle and toward differentiation. The commentary argues that this metabolism-to-translation link could open a new path for testing targeted dietary strategies alongside cancer drugs in future clinical studies.

9 Apr 2026

New 3D organoid model advances pediatric glioma research and treatment

A three-dimensional experimental system has been developed to study the response to drugs in low-grade glioma, a tumor of the central nervous system that often occurs in children.

9 Apr 2026

New combination therapy shows safer approach to treating Alzheimer’s disease

A new study finds that combining the current medications for Alzheimer's disease with small molecules derived from micronutrients found in grapes, berries, peanuts and turmeric is a safer and more effective way to treat the disease.

9 Apr 2026

Novel catalytic approach accelerates synthesis of branched drug compounds

When chemists design drug candidates, shape matters enormously. Many active pharmaceutical ingredients contain branched carbon structures-points where the molecular chain forks in a specific direction-that are critical to whether a molecule will bind to its biological target and whether it will be safe.

9 Apr 2026

OICR funds four Ontario teams to develop next-generation cancer therapies

Better cancer care depends on better treatment options. That's why the Ontario Institute for Cancer Research (OICR) is supporting four Ontario-based research teams working to develop the next generation of cancer therapies that are designed to be more effective at destroying tumors, have reduced side effects, and make cancer less likely to return.

9 Apr 2026

UVA scientists develop AI tools to accelerate new drug discovery

University of Virginia School of Medicine scientists have developed a bold new approach to drug development and discovery that could dramatically accelerate the creation of new medicines.

9 Apr 2026

Study explains why current BET inhibitors fail in cancer treatment

For over a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations.

9 Apr 2026

Fat-producing enzyme identified as key driver of damage in Parkinson’s disease

A fat-producing enzyme in brain cells may play a key role in driving damage in Parkinson's disease and could offer a new target for treatment, scientists at Nanyang Technological University, Singapore (NTU Singapore) have found.

9 Apr 2026

Farm bureau plans are a less pricey alternative to ACA coverage — with trade-offs

Robin Carlton pays about $650 a month for a plan on the Missouri health insurance exchange that covers him and his two teenage kids.

9 Apr 2026

Stem cell study identifies universal checkpoint controlling cell identity

A study published in Cell Research advances a central idea in stem cell biology by identifying a checkpoint that controls the identity of many different types of stem cells across developmental stages.

8 Apr 2026

Sponge and sea slug partnership yields a new anticancer molecule with drug design promise

Researchers identified jorumycidine, a new hexacyclic marine alkaloid from the nudibranch Jorunna funebris and its dietary sponge, Haliclona sp., and demonstrated that it exhibits potent nanomolar cytotoxicity against multiple myeloma cells. They also proposed a new biosynthetic route involving cross-species metabolic interplay and an unusual oxazolidine ring that may help stabilize a pharmacologically important scaffold.

8 Apr 2026

Genetic overlap links psychiatric disorders with many physical ailments

For centuries, mental illness and physical disease have been viewed as two distinct categories, each with its own field of study, its own doctors, and its own menu of treatments.

8 Apr 2026

Insilico Medicine nominates AI-driven drug candidate for cancer, Cushing's syndrome and obesity

The NR3C1 (nuclear receptor subfamily 3 group C member 1) gene encodes the glucocorticoid receptor (GR), a nuclear receptor vital for maintaining physiological homeostasis, and inhibition of NR3C1 could increase the sensitivity of cancer cells to standard chemotherapy, particularly in ovarian cancer.

8 Apr 2026

Yale researchers use zebrafish to find precision treatments for autism

In recent decades, the zebrafish has become one of the most valuable model organisms in scientific research.

8 Apr 2026

Study identifies a common brain activity pattern across psychedelics

Scientists have demonstrated, for the first time, that several psychedelic drugs – including psilocybin, LSD, mescaline, DMT and ayahuasca – produce a common pattern of brain activity despite their distinct chemistries.

8 Apr 2026

High affinity for immune receptors predicts antibody drug associated anaphylaxis risk

Antibody therapeutics are laboratory-made proteins designed to work like the body's natural antibodies. They are widely used to treat diseases such as cancer by binding to specific targets, including cancer cells or inflammatory molecules.

8 Apr 2026

Duloxetine fails to prevent nerve damage caused by chemotherapy

A randomized trial conducted by the Alliance for Clinical Trials in Oncology with support from the National Cancer Institute has found that duloxetine, a medication commonly used to treat chronic pain and psychiatric conditions, does not prevent nerve damage caused by chemotherapy in patients with colorectal cancer.

8 Apr 2026

Long-term study links common IBS medications to mortality risk

A large, long-term study led by Cedars-Sinai Health Sciences University investigators suggests that some medications commonly prescribed to treat irritable bowel syndrome (IBS)-including antidepressants-may be associated with a small but measurable increase in the risk of death.

8 Apr 2026

Urgent care clinics move to fill abortion care gaps in rural areas

Providing abortions was the last thing Shawn Brown thought she'd be doing when she opened an urgent care clinic in this remote town in Michigan's Upper Peninsula.

8 Apr 2026